Erasers of histone acetylation: the histone deacetylase enzymes.

By E. Seto, Minoru Yoshida. Cold Spring Harbor Perspectives in Biology, 2014

1,763 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

HDACs and HDAC Inhibitors in Cancer Development and Therapy (2016, neutral): “By removing the acetyl groups from the 1-amino lysine residues on histone tails, HDACs may play a critical role in transcription regulation (Seto and Yoshida 2014).”
Histone Modifications and Cancer. (2016, background): “They are distinguished from the other classes of HDACs by a distinct catalytic mechanism of action (Seto and Yoshida 2014).”
Epigenetic Determinants of Cancer. (2016, background): “Histone acetylation is associated with open transcriptionally active chromatin regions (see Marmorstein and Zhou 2014; Pirrotta 2014; Seto and Yoshida 2014).”
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials (2019, background): “The human genome harbors 18 different histone deacetylases (53), and it is possible that this drug kills cells by inhibiting HDAC6 and several synthetically redundant HDAC family members.”